Janet Rader
Concepts (632)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uterine Cervical Neoplasms | 84 | 2022 | 277 | 13.420 |
Why?
| Ovarian Neoplasms | 37 | 2024 | 447 | 2.900 |
Why?
| Papillomavirus Infections | 18 | 2021 | 155 | 2.880 |
Why?
| Endometrial Neoplasms | 34 | 2019 | 138 | 2.510 |
Why?
| Uterine Cervical Dysplasia | 16 | 2017 | 49 | 2.500 |
Why?
| Carcinoma, Squamous Cell | 31 | 2018 | 318 | 2.120 |
Why?
| Gene Expression Regulation, Neoplastic | 18 | 2021 | 828 | 1.940 |
Why?
| Human papillomavirus 16 | 8 | 2019 | 44 | 1.790 |
Why?
| Female | 189 | 2024 | 26472 | 1.630 |
Why?
| Gene Expression Profiling | 9 | 2021 | 1032 | 1.600 |
Why?
| Papillomaviridae | 16 | 2020 | 102 | 1.440 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2013 | 989 | 1.350 |
Why?
| DNA Methylation | 21 | 2020 | 548 | 1.340 |
Why?
| Genital Neoplasms, Female | 10 | 2018 | 41 | 1.240 |
Why?
| Human papillomavirus 18 | 5 | 2019 | 9 | 1.220 |
Why?
| Humans | 190 | 2024 | 49974 | 1.180 |
Why?
| Genetic Predisposition to Disease | 13 | 2024 | 510 | 1.160 |
Why?
| Adult | 92 | 2024 | 13236 | 1.150 |
Why?
| Middle Aged | 99 | 2024 | 12069 | 1.090 |
Why?
| Neoplasm Staging | 41 | 2019 | 740 | 1.070 |
Why?
| Adenocarcinoma | 18 | 2018 | 396 | 1.040 |
Why?
| Polymorphism, Single Nucleotide | 10 | 2019 | 485 | 1.000 |
Why?
| Fluorodeoxyglucose F18 | 15 | 2022 | 192 | 0.980 |
Why?
| MicroRNAs | 7 | 2019 | 353 | 0.980 |
Why?
| Neoplasm Recurrence, Local | 19 | 2024 | 614 | 0.970 |
Why?
| DNA-Binding Proteins | 9 | 2021 | 427 | 0.970 |
Why?
| Carcinoma | 12 | 2010 | 138 | 0.930 |
Why?
| Oncogene Proteins, Viral | 4 | 2019 | 52 | 0.880 |
Why?
| Radiopharmaceuticals | 14 | 2022 | 209 | 0.830 |
Why?
| Cervix Uteri | 7 | 2017 | 49 | 0.830 |
Why?
| Repressor Proteins | 4 | 2019 | 151 | 0.820 |
Why?
| Alphapapillomavirus | 1 | 2021 | 13 | 0.790 |
Why?
| DNA, Viral | 6 | 2019 | 133 | 0.770 |
Why?
| Cell Line, Tumor | 18 | 2021 | 1403 | 0.750 |
Why?
| Immunologic Factors | 2 | 2014 | 114 | 0.740 |
Why?
| Neoplasm Invasiveness | 15 | 2020 | 267 | 0.720 |
Why?
| Neoplasms | 8 | 2022 | 1235 | 0.710 |
Why?
| Genetic Markers | 8 | 2017 | 102 | 0.700 |
Why?
| Aged | 70 | 2024 | 9310 | 0.700 |
Why?
| Genes, Tumor Suppressor | 8 | 2007 | 73 | 0.700 |
Why?
| Neoplasm Proteins | 10 | 2019 | 322 | 0.680 |
Why?
| Immunoglobulins | 3 | 2017 | 79 | 0.680 |
Why?
| Genomics | 4 | 2018 | 286 | 0.650 |
Why?
| Biomedical Research | 1 | 2022 | 237 | 0.640 |
Why?
| Gene Silencing | 5 | 2018 | 119 | 0.640 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2017 | 201 | 0.570 |
Why?
| Cisplatin | 7 | 2022 | 278 | 0.570 |
Why?
| Aged, 80 and over | 36 | 2024 | 3129 | 0.550 |
Why?
| Proteomics | 1 | 2019 | 329 | 0.550 |
Why?
| Promoter Regions, Genetic | 12 | 2020 | 475 | 0.540 |
Why?
| HLA-C Antigens | 2 | 2018 | 4 | 0.540 |
Why?
| Receptors, KIR | 2 | 2018 | 13 | 0.530 |
Why?
| Positron-Emission Tomography | 11 | 2013 | 295 | 0.520 |
Why?
| Ubiquitin Thiolesterase | 2 | 2021 | 18 | 0.520 |
Why?
| Tumor Virus Infections | 4 | 2006 | 42 | 0.510 |
Why?
| Microsatellite Repeats | 14 | 2007 | 37 | 0.510 |
Why?
| Lymph Nodes | 10 | 2010 | 260 | 0.510 |
Why?
| Hysterectomy | 15 | 2022 | 88 | 0.500 |
Why?
| Disease-Free Survival | 17 | 2013 | 454 | 0.500 |
Why?
| Gynecologic Surgical Procedures | 4 | 2010 | 30 | 0.500 |
Why?
| Granulosa Cell Tumor | 2 | 2024 | 2 | 0.480 |
Why?
| Phenotype | 4 | 2016 | 729 | 0.470 |
Why?
| Prognosis | 19 | 2021 | 1942 | 0.470 |
Why?
| Lymphatic Metastasis | 14 | 2019 | 224 | 0.460 |
Why?
| Chromosomes, Human, Pair 6 | 4 | 2007 | 15 | 0.450 |
Why?
| Alleles | 5 | 2017 | 250 | 0.450 |
Why?
| Nuclear Proteins | 8 | 2009 | 242 | 0.450 |
Why?
| Loss of Heterozygosity | 10 | 2007 | 77 | 0.450 |
Why?
| Ovary | 2 | 2008 | 104 | 0.430 |
Why?
| Membrane Proteins | 3 | 2005 | 341 | 0.420 |
Why?
| Genotype | 9 | 2018 | 537 | 0.420 |
Why?
| Survival Analysis | 14 | 2021 | 653 | 0.410 |
Why?
| Cell Movement | 5 | 2021 | 247 | 0.410 |
Why?
| STAT3 Transcription Factor | 3 | 2021 | 81 | 0.410 |
Why?
| Peritoneal Neoplasms | 4 | 2008 | 59 | 0.400 |
Why?
| Ultrasonic Therapy | 3 | 2001 | 34 | 0.400 |
Why?
| Carcinoma, Endometrioid | 6 | 2014 | 38 | 0.390 |
Why?
| Genes, p53 | 2 | 2010 | 51 | 0.390 |
Why?
| Cell Proliferation | 6 | 2021 | 1007 | 0.380 |
Why?
| Risk Factors | 13 | 2019 | 3613 | 0.380 |
Why?
| Signal Transduction | 8 | 2021 | 1618 | 0.380 |
Why?
| Uterine Neoplasms | 5 | 2009 | 60 | 0.370 |
Why?
| Mutation | 12 | 2018 | 1294 | 0.370 |
Why?
| Ascites | 2 | 2008 | 28 | 0.370 |
Why?
| Carboplatin | 2 | 2009 | 53 | 0.360 |
Why?
| Antineoplastic Agents | 9 | 2014 | 1171 | 0.360 |
Why?
| Antibodies, Monoclonal | 5 | 2021 | 459 | 0.360 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2010 | 14 | 0.360 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 12 | 0.360 |
Why?
| Cohort Studies | 13 | 2024 | 1422 | 0.360 |
Why?
| Disease Progression | 6 | 2020 | 825 | 0.350 |
Why?
| GTPase-Activating Proteins | 1 | 2009 | 23 | 0.350 |
Why?
| Membrane Glycoproteins | 2 | 2009 | 240 | 0.350 |
Why?
| Base Sequence | 8 | 2019 | 643 | 0.350 |
Why?
| DNA, Neoplasm | 11 | 2006 | 147 | 0.340 |
Why?
| Chromosomes, Human, Pair 11 | 3 | 2005 | 54 | 0.340 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2009 | 88 | 0.340 |
Why?
| Neoplasms, Glandular and Epithelial | 3 | 2006 | 42 | 0.340 |
Why?
| Brachytherapy | 9 | 2014 | 48 | 0.330 |
Why?
| Proto-Oncogene Proteins c-myc | 2 | 2021 | 50 | 0.330 |
Why?
| Combined Modality Therapy | 11 | 2010 | 637 | 0.330 |
Why?
| Abdominal Neoplasms | 1 | 2009 | 16 | 0.330 |
Why?
| DNA Repair | 11 | 2007 | 193 | 0.330 |
Why?
| Retrospective Studies | 33 | 2024 | 6108 | 0.330 |
Why?
| Laser Coagulation | 1 | 2009 | 26 | 0.330 |
Why?
| Drug Administration Schedule | 10 | 2013 | 376 | 0.320 |
Why?
| Deoxycytidine | 4 | 2006 | 27 | 0.310 |
Why?
| Homeodomain Proteins | 2 | 2006 | 80 | 0.310 |
Why?
| RNA-Binding Proteins | 2 | 2021 | 123 | 0.310 |
Why?
| Microsatellite Instability | 5 | 2019 | 17 | 0.310 |
Why?
| Germ-Line Mutation | 3 | 2024 | 61 | 0.310 |
Why?
| Protozoan Proteins | 1 | 2008 | 31 | 0.310 |
Why?
| Laparoscopy | 3 | 2022 | 170 | 0.310 |
Why?
| Kaplan-Meier Estimate | 6 | 2019 | 466 | 0.300 |
Why?
| Drug Resistance, Neoplasm | 6 | 2016 | 308 | 0.300 |
Why?
| Ovariectomy | 7 | 2010 | 119 | 0.300 |
Why?
| Antigens, CD | 2 | 2007 | 219 | 0.290 |
Why?
| Chromosomes, Human, Pair 3 | 4 | 2001 | 19 | 0.290 |
Why?
| Heart Arrest | 1 | 2009 | 149 | 0.290 |
Why?
| SOXC Transcription Factors | 2 | 2019 | 13 | 0.290 |
Why?
| Polymerase Chain Reaction | 9 | 2010 | 453 | 0.280 |
Why?
| Receptors, Estrogen | 3 | 2024 | 130 | 0.280 |
Why?
| Topotecan | 5 | 2013 | 17 | 0.280 |
Why?
| POU Domain Factors | 1 | 2006 | 1 | 0.280 |
Why?
| Vulvar Neoplasms | 5 | 2002 | 52 | 0.270 |
Why?
| Registries | 6 | 2010 | 522 | 0.270 |
Why?
| Neoplasm Metastasis | 5 | 2021 | 231 | 0.270 |
Why?
| Oligonucleotide Array Sequence Analysis | 5 | 2010 | 411 | 0.270 |
Why?
| HeLa Cells | 3 | 2021 | 250 | 0.270 |
Why?
| Anemia | 3 | 2020 | 68 | 0.260 |
Why?
| Young Adult | 7 | 2018 | 3958 | 0.260 |
Why?
| Survival Rate | 10 | 2009 | 894 | 0.260 |
Why?
| Vaginal Smears | 6 | 2006 | 28 | 0.260 |
Why?
| Breast Neoplasms | 5 | 2018 | 1174 | 0.250 |
Why?
| Immunohistochemistry | 12 | 2024 | 973 | 0.250 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2007 | 595 | 0.240 |
Why?
| Chromosome Aberrations | 1 | 2006 | 297 | 0.240 |
Why?
| Virus Integration | 2 | 2021 | 8 | 0.230 |
Why?
| HSP70 Heat-Shock Proteins | 1 | 2004 | 62 | 0.230 |
Why?
| Receptors, Androgen | 1 | 2024 | 46 | 0.230 |
Why?
| Receptors, Progesterone | 1 | 2024 | 63 | 0.230 |
Why?
| Cystadenocarcinoma, Papillary | 2 | 2002 | 14 | 0.230 |
Why?
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2003 | 16 | 0.230 |
Why?
| Oncostatin M | 2 | 2021 | 5 | 0.230 |
Why?
| Quinazolines | 1 | 2003 | 33 | 0.230 |
Why?
| Antigens, Neoplasm | 1 | 2004 | 151 | 0.220 |
Why?
| Genome-Wide Association Study | 2 | 2017 | 166 | 0.220 |
Why?
| Polymorphism, Genetic | 5 | 2018 | 181 | 0.220 |
Why?
| Small Cell Lung Carcinoma | 1 | 2023 | 26 | 0.220 |
Why?
| Omentum | 1 | 2002 | 14 | 0.220 |
Why?
| Case-Control Studies | 7 | 2019 | 1131 | 0.220 |
Why?
| Treatment Outcome | 23 | 2014 | 5141 | 0.210 |
Why?
| Chromosome Deletion | 3 | 2000 | 140 | 0.210 |
Why?
| Linkage Disequilibrium | 3 | 2017 | 37 | 0.210 |
Why?
| Tumor Microenvironment | 2 | 2021 | 212 | 0.210 |
Why?
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 157 | 0.210 |
Why?
| Neoadjuvant Therapy | 2 | 2022 | 114 | 0.210 |
Why?
| Antibodies, Monoclonal, Humanized | 5 | 2013 | 225 | 0.200 |
Why?
| Genetic Variation | 4 | 2019 | 213 | 0.200 |
Why?
| Eukaryotic Initiation Factor-4F | 1 | 2021 | 1 | 0.200 |
Why?
| Postoperative Complications | 3 | 2022 | 984 | 0.200 |
Why?
| Base Pair Mismatch | 5 | 2006 | 22 | 0.200 |
Why?
| CA-125 Antigen | 3 | 2008 | 17 | 0.200 |
Why?
| Chemoradiotherapy | 1 | 2022 | 40 | 0.200 |
Why?
| Suction | 1 | 2001 | 23 | 0.200 |
Why?
| Oncostatin M Receptor beta Subunit | 1 | 2021 | 1 | 0.200 |
Why?
| Smoking | 1 | 2005 | 511 | 0.190 |
Why?
| Radiotherapy, Conformal | 2 | 2014 | 53 | 0.190 |
Why?
| Colorectal Neoplasms | 3 | 2002 | 236 | 0.190 |
Why?
| Proteins | 5 | 2008 | 342 | 0.190 |
Why?
| Carcinoma in Situ | 2 | 2013 | 73 | 0.190 |
Why?
| Adaptor Proteins, Signal Transducing | 8 | 2007 | 197 | 0.190 |
Why?
| Antimetabolites, Antineoplastic | 2 | 2002 | 37 | 0.190 |
Why?
| Gene Regulatory Networks | 2 | 2019 | 107 | 0.190 |
Why?
| Fetofetal Transfusion | 1 | 2020 | 6 | 0.190 |
Why?
| Polycythemia | 1 | 2020 | 9 | 0.190 |
Why?
| Pregnancy, Twin | 1 | 2020 | 8 | 0.190 |
Why?
| Minority Groups | 1 | 2022 | 132 | 0.190 |
Why?
| Twins, Monozygotic | 1 | 2020 | 17 | 0.180 |
Why?
| Radiotherapy | 3 | 2010 | 128 | 0.180 |
Why?
| Sarcoma | 3 | 2009 | 67 | 0.180 |
Why?
| Lymph Node Excision | 7 | 2019 | 134 | 0.180 |
Why?
| Genetic Diseases, Inborn | 1 | 2000 | 24 | 0.180 |
Why?
| Transcriptome | 2 | 2020 | 315 | 0.180 |
Why?
| Patient Satisfaction | 2 | 2006 | 273 | 0.180 |
Why?
| Phosphoproteins | 2 | 2016 | 107 | 0.180 |
Why?
| Receptor, erbB-3 | 1 | 2020 | 1 | 0.180 |
Why?
| Furin | 1 | 2020 | 3 | 0.180 |
Why?
| HLA-DQ Antigens | 1 | 2000 | 3 | 0.180 |
Why?
| Receptor, IGF Type 1 | 1 | 2020 | 20 | 0.180 |
Why?
| Tomography, X-Ray Computed | 7 | 2013 | 1159 | 0.170 |
Why?
| Mice, Nude | 4 | 2021 | 252 | 0.170 |
Why?
| Tumor Cells, Cultured | 7 | 2021 | 465 | 0.170 |
Why?
| RNA, Neoplasm | 3 | 2007 | 44 | 0.170 |
Why?
| Students | 1 | 2022 | 210 | 0.170 |
Why?
| Prenatal Diagnosis | 1 | 2020 | 107 | 0.170 |
Why?
| Antibodies, Neoplasm | 1 | 2019 | 28 | 0.170 |
Why?
| Papillomavirus E7 Proteins | 2 | 2017 | 31 | 0.170 |
Why?
| Adolescent | 13 | 2018 | 6356 | 0.170 |
Why?
| NM23 Nucleoside Diphosphate Kinases | 1 | 2019 | 4 | 0.170 |
Why?
| Placenta | 1 | 2020 | 132 | 0.170 |
Why?
| Reproducibility of Results | 2 | 2022 | 1193 | 0.160 |
Why?
| Indocyanine Green | 1 | 2019 | 34 | 0.160 |
Why?
| Follow-Up Studies | 13 | 2019 | 2182 | 0.160 |
Why?
| Doxorubicin | 4 | 2009 | 233 | 0.160 |
Why?
| Decision Making | 1 | 2001 | 265 | 0.160 |
Why?
| Fallopian Tube Neoplasms | 3 | 2008 | 14 | 0.160 |
Why?
| Salvage Therapy | 3 | 2008 | 139 | 0.160 |
Why?
| Cyclooxygenase 2 | 2 | 2017 | 45 | 0.160 |
Why?
| Sequence Analysis, DNA | 1 | 2019 | 237 | 0.150 |
Why?
| Lung Neoplasms | 2 | 2023 | 606 | 0.150 |
Why?
| HLA-DRB1 Chains | 1 | 2017 | 4 | 0.150 |
Why?
| HLA-B Antigens | 1 | 2017 | 6 | 0.150 |
Why?
| Transcription Factors | 1 | 2021 | 561 | 0.150 |
Why?
| Metabolic Networks and Pathways | 1 | 2018 | 89 | 0.150 |
Why?
| DNA Copy Number Variations | 1 | 2018 | 110 | 0.150 |
Why?
| Receptors, Vitronectin | 1 | 1997 | 1 | 0.150 |
Why?
| Tumor Suppressor Proteins | 3 | 2005 | 128 | 0.150 |
Why?
| Carcinoma, Adenosquamous | 3 | 2009 | 8 | 0.150 |
Why?
| Proto-Oncogene Proteins | 5 | 2004 | 149 | 0.150 |
Why?
| DNA Mutational Analysis | 9 | 2005 | 175 | 0.150 |
Why?
| Interleukin-10 | 1 | 2017 | 84 | 0.150 |
Why?
| Adipose Tissue | 1 | 2019 | 187 | 0.150 |
Why?
| Bayes Theorem | 1 | 2017 | 109 | 0.150 |
Why?
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 19 | 0.140 |
Why?
| In Situ Hybridization | 3 | 2008 | 65 | 0.140 |
Why?
| Leukocytes, Mononuclear | 1 | 2017 | 116 | 0.140 |
Why?
| Protein Binding | 1 | 2019 | 660 | 0.140 |
Why?
| Radiotherapy, Intensity-Modulated | 2 | 2009 | 172 | 0.140 |
Why?
| Gene Expression Regulation, Viral | 1 | 2017 | 48 | 0.140 |
Why?
| Animals | 10 | 2021 | 13187 | 0.140 |
Why?
| Risk Assessment | 9 | 2019 | 1259 | 0.140 |
Why?
| Body Mass Index | 3 | 2010 | 652 | 0.140 |
Why?
| Radiotherapy Dosage | 8 | 2014 | 244 | 0.140 |
Why?
| ROC Curve | 1 | 2017 | 232 | 0.140 |
Why?
| Radiation Injuries | 3 | 2008 | 113 | 0.140 |
Why?
| Taxoids | 3 | 2006 | 37 | 0.140 |
Why?
| Carrier Proteins | 7 | 2006 | 304 | 0.130 |
Why?
| Biopsy | 5 | 2006 | 584 | 0.130 |
Why?
| Prospective Studies | 10 | 2019 | 2364 | 0.130 |
Why?
| Estrogens | 1 | 2017 | 227 | 0.130 |
Why?
| Colposcopy | 3 | 2006 | 18 | 0.130 |
Why?
| Molecular Sequence Data | 5 | 2009 | 792 | 0.130 |
Why?
| Wound Healing | 2 | 2018 | 204 | 0.130 |
Why?
| Cells, Cultured | 2 | 2017 | 1573 | 0.130 |
Why?
| Carcinosarcoma | 3 | 2019 | 18 | 0.130 |
Why?
| Double-Blind Method | 1 | 2017 | 681 | 0.130 |
Why?
| Algorithms | 1 | 2019 | 615 | 0.130 |
Why?
| Sensitivity and Specificity | 4 | 2006 | 861 | 0.130 |
Why?
| Apoptosis | 2 | 2021 | 1101 | 0.130 |
Why?
| Mice | 6 | 2021 | 5739 | 0.120 |
Why?
| Ultrasonography, Doppler, Color | 1 | 1995 | 33 | 0.120 |
Why?
| Protein Kinase Inhibitors | 2 | 2014 | 204 | 0.120 |
Why?
| Aneurysm | 1 | 1995 | 33 | 0.120 |
Why?
| Dose-Response Relationship, Drug | 6 | 2008 | 1376 | 0.120 |
Why?
| DNA Primers | 2 | 2006 | 207 | 0.120 |
Why?
| Phosphatidylinositol 3-Kinases | 2 | 2014 | 141 | 0.120 |
Why?
| Platinum Compounds | 4 | 2008 | 10 | 0.120 |
Why?
| Obesity | 5 | 2010 | 1113 | 0.120 |
Why?
| Heterocyclic Compounds, 3-Ring | 1 | 2014 | 4 | 0.120 |
Why?
| Cyclohexanones | 1 | 2014 | 7 | 0.120 |
Why?
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2004 | 11 | 0.120 |
Why?
| Embolization, Therapeutic | 1 | 1995 | 88 | 0.110 |
Why?
| Transcriptional Activation | 2 | 2019 | 121 | 0.110 |
Why?
| Camptothecin | 3 | 2010 | 16 | 0.110 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2014 | 77 | 0.110 |
Why?
| Genetic Association Studies | 1 | 2014 | 117 | 0.110 |
Why?
| Paclitaxel | 4 | 2007 | 84 | 0.110 |
Why?
| Introns | 1 | 2013 | 48 | 0.110 |
Why?
| Hypercalcemia | 1 | 1993 | 33 | 0.110 |
Why?
| Decision Support Techniques | 2 | 2010 | 70 | 0.110 |
Why?
| Chromosome Mapping | 3 | 2005 | 156 | 0.110 |
Why?
| Pyridines | 1 | 2014 | 130 | 0.110 |
Why?
| Cell Transformation, Neoplastic | 2 | 2006 | 177 | 0.110 |
Why?
| Brain Neoplasms | 1 | 2016 | 287 | 0.110 |
Why?
| Dermatologic Surgical Procedures | 1 | 1992 | 34 | 0.100 |
Why?
| Models, Genetic | 1 | 2012 | 170 | 0.100 |
Why?
| Tomography, Emission-Computed | 4 | 2005 | 53 | 0.100 |
Why?
| Groin | 2 | 2002 | 16 | 0.100 |
Why?
| Keratinocytes | 2 | 2006 | 90 | 0.100 |
Why?
| RNA, Messenger | 4 | 2021 | 1105 | 0.100 |
Why?
| Glucose | 1 | 2014 | 344 | 0.100 |
Why?
| Laser Therapy | 1 | 1992 | 84 | 0.100 |
Why?
| Exons | 3 | 2007 | 95 | 0.100 |
Why?
| Pyrazoles | 2 | 2023 | 113 | 0.100 |
Why?
| Infusions, Intravenous | 4 | 2006 | 206 | 0.100 |
Why?
| Heterozygote | 2 | 2004 | 81 | 0.100 |
Why?
| Condylomata Acuminata | 1 | 1991 | 4 | 0.100 |
Why?
| Magnetic Resonance Imaging | 3 | 2014 | 1537 | 0.100 |
Why?
| Models, Statistical | 1 | 2012 | 224 | 0.100 |
Why?
| Epithelium | 2 | 2007 | 65 | 0.100 |
Why?
| Goserelin | 1 | 2010 | 1 | 0.100 |
Why?
| Decision Trees | 1 | 2010 | 19 | 0.090 |
Why?
| Estrogen Antagonists | 1 | 2010 | 21 | 0.090 |
Why?
| Ileal Diseases | 1 | 1990 | 4 | 0.090 |
Why?
| Predictive Value of Tests | 6 | 2010 | 903 | 0.090 |
Why?
| Leiomyoma | 1 | 1990 | 25 | 0.090 |
Why?
| Epigenesis, Genetic | 2 | 2019 | 374 | 0.090 |
Why?
| Cell Differentiation | 2 | 2009 | 651 | 0.090 |
Why?
| Polymorphism, Restriction Fragment Length | 1 | 2010 | 66 | 0.090 |
Why?
| Restriction Mapping | 3 | 2006 | 32 | 0.090 |
Why?
| Gastrointestinal Hemorrhage | 1 | 1990 | 78 | 0.090 |
Why?
| Diagnosis, Differential | 3 | 2020 | 1037 | 0.090 |
Why?
| Colonic Neoplasms | 2 | 2004 | 161 | 0.090 |
Why?
| Skin Transplantation | 1 | 1990 | 43 | 0.090 |
Why?
| Age Factors | 4 | 2006 | 1087 | 0.090 |
Why?
| Down-Regulation | 4 | 2020 | 348 | 0.090 |
Why?
| Maximum Tolerated Dose | 5 | 2010 | 37 | 0.080 |
Why?
| Fluorouracil | 2 | 2006 | 54 | 0.080 |
Why?
| Endometrium | 3 | 2019 | 41 | 0.080 |
Why?
| Genome, Human | 2 | 2008 | 111 | 0.080 |
Why?
| Urinary Bladder Diseases | 1 | 2009 | 18 | 0.080 |
Why?
| Intestinal Diseases | 1 | 2009 | 25 | 0.080 |
Why?
| Lymphatic Vessels | 1 | 2009 | 48 | 0.080 |
Why?
| Lasers, Gas | 1 | 2009 | 7 | 0.080 |
Why?
| Embolism, Air | 1 | 2009 | 12 | 0.080 |
Why?
| Transcription, Genetic | 4 | 2019 | 369 | 0.080 |
Why?
| Vaginal Neoplasms | 2 | 2005 | 4 | 0.080 |
Why?
| Adenocarcinoma, Clear Cell | 3 | 2019 | 34 | 0.080 |
Why?
| Fluorine Radioisotopes | 1 | 2008 | 24 | 0.080 |
Why?
| Primary Ovarian Insufficiency | 1 | 2008 | 4 | 0.080 |
Why?
| Infertility, Female | 1 | 2008 | 18 | 0.080 |
Why?
| Eimeria | 1 | 2008 | 3 | 0.080 |
Why?
| Haplotypes | 2 | 2017 | 83 | 0.080 |
Why?
| Polyethylene Glycols | 2 | 2006 | 93 | 0.080 |
Why?
| Ubiquitin | 1 | 2008 | 45 | 0.080 |
Why?
| Up-Regulation | 2 | 2020 | 452 | 0.080 |
Why?
| Cell Cycle Proteins | 1 | 2009 | 166 | 0.080 |
Why?
| Cricetinae | 1 | 2008 | 192 | 0.080 |
Why?
| Expressed Sequence Tags | 1 | 2007 | 8 | 0.080 |
Why?
| Tumor Burden | 2 | 2021 | 132 | 0.080 |
Why?
| Angiogenesis Inhibitors | 2 | 2006 | 187 | 0.080 |
Why?
| Infusion Pumps | 1 | 1987 | 13 | 0.080 |
Why?
| Fluorescent Antibody Technique | 1 | 2007 | 108 | 0.080 |
Why?
| Diagnostic Imaging | 1 | 2009 | 176 | 0.070 |
Why?
| Microdissection | 1 | 2007 | 19 | 0.070 |
Why?
| Precancerous Conditions | 2 | 2005 | 83 | 0.070 |
Why?
| Models, Biological | 2 | 2008 | 727 | 0.070 |
Why?
| MutS Homolog 2 Protein | 5 | 2007 | 12 | 0.070 |
Why?
| Aorta | 3 | 2005 | 161 | 0.070 |
Why?
| Stromal Cells | 1 | 2007 | 72 | 0.070 |
Why?
| Organ Specificity | 2 | 2018 | 108 | 0.070 |
Why?
| Codon | 2 | 2003 | 47 | 0.070 |
Why?
| Lasers | 1 | 2007 | 123 | 0.070 |
Why?
| Pelvic Floor | 1 | 2007 | 51 | 0.070 |
Why?
| RNA, Double-Stranded | 1 | 2006 | 21 | 0.070 |
Why?
| Polymorphism, Single-Stranded Conformational | 6 | 2003 | 19 | 0.070 |
Why?
| Neutropenia | 1 | 2007 | 116 | 0.070 |
Why?
| Recombinant Proteins | 1 | 2008 | 486 | 0.070 |
Why?
| Tissue Fixation | 1 | 2006 | 36 | 0.070 |
Why?
| Intestinal Perforation | 2 | 2006 | 23 | 0.070 |
Why?
| Head and Neck Neoplasms | 2 | 2016 | 268 | 0.070 |
Why?
| Specimen Handling | 1 | 2006 | 55 | 0.070 |
Why?
| Pulmonary Embolism | 1 | 1987 | 97 | 0.070 |
Why?
| Protein Kinases | 1 | 2006 | 71 | 0.070 |
Why?
| Chromosomes, Artificial, Yeast | 3 | 2000 | 6 | 0.070 |
Why?
| Endometrial Hyperplasia | 2 | 2002 | 14 | 0.060 |
Why?
| Proportional Hazards Models | 4 | 2010 | 402 | 0.060 |
Why?
| Abdomen | 1 | 2006 | 76 | 0.060 |
Why?
| Papillomavirus Vaccines | 1 | 2006 | 61 | 0.060 |
Why?
| Recurrence | 4 | 2010 | 652 | 0.060 |
Why?
| Probability | 4 | 2007 | 164 | 0.060 |
Why?
| Terminal Care | 1 | 2005 | 45 | 0.060 |
Why?
| Dibenzocycloheptenes | 1 | 2004 | 1 | 0.060 |
Why?
| Neovascularization, Pathologic | 1 | 2006 | 161 | 0.060 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2006 | 202 | 0.060 |
Why?
| Male | 11 | 2018 | 25241 | 0.060 |
Why?
| Radiation-Sensitizing Agents | 1 | 2005 | 53 | 0.060 |
Why?
| Quinolines | 1 | 2004 | 40 | 0.060 |
Why?
| Cell Adhesion Molecules | 1 | 2005 | 88 | 0.060 |
Why?
| Amyloid | 1 | 2004 | 28 | 0.060 |
Why?
| Tissue Distribution | 1 | 2004 | 163 | 0.060 |
Why?
| Genes, Viral | 1 | 2003 | 37 | 0.060 |
Why?
| Lactones | 1 | 2003 | 26 | 0.060 |
Why?
| Abdomen, Acute | 1 | 2003 | 6 | 0.060 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 244 | 0.060 |
Why?
| Thrombospondins | 1 | 2003 | 8 | 0.060 |
Why?
| Biopsy, Needle | 4 | 2006 | 183 | 0.060 |
Why?
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2003 | 57 | 0.060 |
Why?
| Pyrimidinones | 1 | 2023 | 17 | 0.060 |
Why?
| Obesity, Morbid | 1 | 2004 | 78 | 0.060 |
Why?
| RNA, Viral | 2 | 2016 | 125 | 0.060 |
Why?
| Fibroma | 1 | 2003 | 39 | 0.060 |
Why?
| Clinical Competence | 1 | 2006 | 393 | 0.050 |
Why?
| Radiotherapy, Adjuvant | 3 | 2010 | 56 | 0.050 |
Why?
| Neoplasms, Second Primary | 1 | 2004 | 78 | 0.050 |
Why?
| Congenital Abnormalities | 1 | 2004 | 112 | 0.050 |
Why?
| Uterine Hemorrhage | 1 | 2002 | 11 | 0.050 |
Why?
| Age of Onset | 2 | 2004 | 108 | 0.050 |
Why?
| Pneumatosis Cystoides Intestinalis | 1 | 2002 | 7 | 0.050 |
Why?
| PTEN Phosphohydrolase | 2 | 2019 | 55 | 0.050 |
Why?
| DNA, Ribosomal | 1 | 2002 | 28 | 0.050 |
Why?
| Blood Transfusion, Autologous | 1 | 2002 | 4 | 0.050 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2003 | 349 | 0.050 |
Why?
| Genital Diseases, Female | 1 | 2002 | 17 | 0.050 |
Why?
| Acridines | 1 | 2002 | 4 | 0.050 |
Why?
| Medical History Taking | 1 | 2002 | 47 | 0.050 |
Why?
| Pregnancy | 3 | 2020 | 2607 | 0.050 |
Why?
| Medical Records | 1 | 2002 | 83 | 0.050 |
Why?
| Blood Donors | 1 | 2002 | 31 | 0.050 |
Why?
| Complementary Therapies | 1 | 2002 | 25 | 0.050 |
Why?
| AU Rich Elements | 1 | 2021 | 1 | 0.050 |
Why?
| Family Health | 1 | 2002 | 80 | 0.050 |
Why?
| Postmenopause | 1 | 2002 | 100 | 0.050 |
Why?
| Peptide Chain Initiation, Translational | 1 | 2021 | 15 | 0.050 |
Why?
| RNA Stability | 1 | 2021 | 24 | 0.050 |
Why?
| Cytokine Receptor gp130 | 1 | 2021 | 12 | 0.050 |
Why?
| Receptors, Transforming Growth Factor beta | 1 | 2001 | 25 | 0.050 |
Why?
| 3' Untranslated Regions | 1 | 2021 | 52 | 0.050 |
Why?
| Lymphatic Irradiation | 1 | 2001 | 1 | 0.050 |
Why?
| Blotting, Northern | 2 | 2001 | 109 | 0.050 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 26 | 0.050 |
Why?
| Blotting, Southern | 3 | 2002 | 42 | 0.050 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2021 | 211 | 0.050 |
Why?
| Phosphoric Monoester Hydrolases | 1 | 2000 | 22 | 0.050 |
Why?
| Equipment Design | 1 | 2001 | 284 | 0.050 |
Why?
| Internship and Residency | 1 | 2006 | 443 | 0.050 |
Why?
| Blood Vessels | 1 | 2001 | 72 | 0.050 |
Why?
| Uganda | 1 | 2020 | 36 | 0.050 |
Why?
| Catheterization, Central Venous | 1 | 2001 | 86 | 0.050 |
Why?
| Isoenzymes | 1 | 2001 | 168 | 0.050 |
Why?
| Logistic Models | 2 | 2017 | 888 | 0.050 |
Why?
| Quality Improvement | 1 | 2022 | 208 | 0.050 |
Why?
| Risk Management | 1 | 2000 | 32 | 0.050 |
Why?
| Incidence | 3 | 2007 | 1003 | 0.050 |
Why?
| Physical Chromosome Mapping | 1 | 2000 | 8 | 0.050 |
Why?
| beta Karyopherins | 1 | 2019 | 4 | 0.040 |
Why?
| Patient Discharge | 1 | 2022 | 320 | 0.040 |
Why?
| Interviews as Topic | 1 | 2001 | 259 | 0.040 |
Why?
| Acid Anhydride Hydrolases | 1 | 1999 | 15 | 0.040 |
Why?
| Cell Survival | 1 | 2021 | 600 | 0.040 |
Why?
| DNA Repair Enzymes | 1 | 1999 | 44 | 0.040 |
Why?
| Adenosine Triphosphatases | 1 | 1999 | 87 | 0.040 |
Why?
| Cell Nucleus | 1 | 2019 | 183 | 0.040 |
Why?
| Molecular Targeted Therapy | 1 | 2019 | 119 | 0.040 |
Why?
| Cross-Sectional Studies | 1 | 2024 | 1557 | 0.040 |
Why?
| Regression Analysis | 3 | 2006 | 395 | 0.040 |
Why?
| Pregnancy Outcome | 1 | 2020 | 237 | 0.040 |
Why?
| Chromosomes, Human, Pair 10 | 1 | 1998 | 3 | 0.040 |
Why?
| Coloring Agents | 1 | 2019 | 69 | 0.040 |
Why?
| Cystadenocarcinoma, Serous | 1 | 2019 | 70 | 0.040 |
Why?
| Gene Dosage | 1 | 2018 | 78 | 0.040 |
Why?
| Histone Demethylases | 1 | 2018 | 16 | 0.040 |
Why?
| Th1-Th2 Balance | 1 | 2018 | 2 | 0.040 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2018 | 47 | 0.040 |
Why?
| Leptin | 1 | 2019 | 140 | 0.040 |
Why?
| Major Histocompatibility Complex | 1 | 2017 | 11 | 0.040 |
Why?
| Databases, Genetic | 1 | 2018 | 88 | 0.040 |
Why?
| Genotyping Techniques | 1 | 2017 | 20 | 0.040 |
Why?
| Estradiol | 1 | 2019 | 225 | 0.040 |
Why?
| Child | 4 | 2018 | 6847 | 0.040 |
Why?
| Chemokines | 1 | 2017 | 77 | 0.040 |
Why?
| Receptors, Collagen | 1 | 1997 | 3 | 0.040 |
Why?
| Receptors, Fibronectin | 1 | 1997 | 5 | 0.040 |
Why?
| Coculture Techniques | 1 | 2017 | 146 | 0.040 |
Why?
| Interferon-gamma | 1 | 2018 | 177 | 0.040 |
Why?
| Time Factors | 4 | 2010 | 2903 | 0.040 |
Why?
| Transforming Growth Factor beta | 1 | 2018 | 144 | 0.040 |
Why?
| Integrins | 1 | 1997 | 31 | 0.040 |
Why?
| Mass Screening | 1 | 2000 | 353 | 0.040 |
Why?
| Chemotherapy, Adjuvant | 2 | 2010 | 119 | 0.040 |
Why?
| Quality-Adjusted Life Years | 2 | 2010 | 63 | 0.040 |
Why?
| Diet, High-Fat | 1 | 2019 | 222 | 0.040 |
Why?
| Longitudinal Studies | 1 | 2019 | 688 | 0.040 |
Why?
| Hepatitis Viruses | 1 | 2016 | 2 | 0.030 |
Why?
| Epithelial Cells | 2 | 2006 | 209 | 0.030 |
Why?
| Herpesviridae | 1 | 2016 | 17 | 0.030 |
Why?
| Viruses | 1 | 2016 | 21 | 0.030 |
Why?
| Host-Pathogen Interactions | 1 | 2017 | 134 | 0.030 |
Why?
| Gastrointestinal Neoplasms | 1 | 2016 | 44 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2017 | 555 | 0.030 |
Why?
| DNA Replication | 1 | 1997 | 150 | 0.030 |
Why?
| Cost-Benefit Analysis | 2 | 2010 | 274 | 0.030 |
Why?
| Plasmids | 2 | 2001 | 161 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2016 | 91 | 0.030 |
Why?
| Central Nervous System Neoplasms | 1 | 2016 | 63 | 0.030 |
Why?
| Electrosurgery | 1 | 1995 | 7 | 0.030 |
Why?
| Fibroblasts | 1 | 2017 | 345 | 0.030 |
Why?
| Macrophages | 1 | 2018 | 363 | 0.030 |
Why?
| Prostatic Neoplasms | 1 | 1998 | 394 | 0.030 |
Why?
| CpG Islands | 2 | 2008 | 108 | 0.030 |
Why?
| DNA Probes, HPV | 2 | 1991 | 3 | 0.030 |
Why?
| Computational Biology | 1 | 2016 | 214 | 0.030 |
Why?
| Arteries | 1 | 1995 | 93 | 0.030 |
Why?
| Cytokines | 1 | 2017 | 612 | 0.030 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 18 | 0.030 |
Why?
| Multivariate Analysis | 2 | 2009 | 577 | 0.030 |
Why?
| Treatment Failure | 2 | 2008 | 114 | 0.030 |
Why?
| Missouri | 2 | 2006 | 65 | 0.030 |
Why?
| Organs at Risk | 1 | 2014 | 69 | 0.030 |
Why?
| Inclusion Bodies | 1 | 1993 | 17 | 0.030 |
Why?
| Parathyroid Hormone-Related Protein | 1 | 1993 | 23 | 0.030 |
Why?
| Cell Division | 2 | 1994 | 292 | 0.030 |
Why?
| Cell Death | 1 | 2014 | 181 | 0.030 |
Why?
| Imaging, Three-Dimensional | 1 | 2014 | 151 | 0.030 |
Why?
| Risk | 2 | 2004 | 320 | 0.030 |
Why?
| Skin Physiological Phenomena | 1 | 1992 | 15 | 0.030 |
Why?
| Guinea Pigs | 1 | 1992 | 74 | 0.030 |
Why?
| Epidermis | 1 | 1992 | 27 | 0.030 |
Why?
| Pelvis | 2 | 2004 | 68 | 0.030 |
Why?
| Pedigree | 2 | 2004 | 125 | 0.030 |
Why?
| Deoxyglucose | 1 | 2012 | 36 | 0.030 |
Why?
| Regeneration | 1 | 1992 | 72 | 0.030 |
Why?
| Colectomy | 1 | 1992 | 30 | 0.030 |
Why?
| Computer Simulation | 1 | 2012 | 280 | 0.020 |
Why?
| Pilot Projects | 2 | 2004 | 699 | 0.020 |
Why?
| Sequence Deletion | 2 | 2003 | 66 | 0.020 |
Why?
| Premenopause | 1 | 2010 | 24 | 0.020 |
Why?
| Amino Acid Sequence | 2 | 2003 | 585 | 0.020 |
Why?
| Staurosporine | 1 | 2010 | 12 | 0.020 |
Why?
| Anastomosis, Surgical | 1 | 1990 | 66 | 0.020 |
Why?
| Remission Induction | 1 | 2010 | 207 | 0.020 |
Why?
| Molecular Weight | 1 | 1990 | 84 | 0.020 |
Why?
| Proto-Oncogene Proteins p21(ras) | 2 | 2001 | 66 | 0.020 |
Why?
| ras Proteins | 2 | 2001 | 64 | 0.020 |
Why?
| Cicatrix | 1 | 1990 | 40 | 0.020 |
Why?
| Hemoglobins | 1 | 1990 | 107 | 0.020 |
Why?
| Staining and Labeling | 1 | 1990 | 97 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2010 | 280 | 0.020 |
Why?
| Perioperative Care | 1 | 2009 | 41 | 0.020 |
Why?
| Urinary Incontinence | 1 | 2009 | 38 | 0.020 |
Why?
| Organoplatinum Compounds | 1 | 2008 | 14 | 0.020 |
Why?
| Gene Knockdown Techniques | 1 | 2009 | 106 | 0.020 |
Why?
| Vinblastine | 1 | 2008 | 23 | 0.020 |
Why?
| Fetus | 1 | 1990 | 217 | 0.020 |
Why?
| Life Style | 1 | 2009 | 140 | 0.020 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2008 | 184 | 0.020 |
Why?
| Emotions | 1 | 2009 | 165 | 0.020 |
Why?
| Demography | 1 | 2007 | 93 | 0.020 |
Why?
| Cadherins | 1 | 2007 | 68 | 0.020 |
Why?
| Cell Line | 1 | 1990 | 1000 | 0.020 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 142 | 0.020 |
Why?
| Cytoplasmic Structures | 1 | 2006 | 1 | 0.020 |
Why?
| Skin | 1 | 1990 | 409 | 0.020 |
Why?
| Waxes | 1 | 2006 | 1 | 0.020 |
Why?
| Tissue Embedding | 1 | 2006 | 1 | 0.020 |
Why?
| Eukaryotic Initiation Factor-2 | 1 | 2006 | 18 | 0.020 |
Why?
| DNA Mismatch Repair | 1 | 2006 | 17 | 0.020 |
Why?
| NIH 3T3 Cells | 1 | 2006 | 52 | 0.020 |
Why?
| Immunoenzyme Techniques | 2 | 2001 | 143 | 0.020 |
Why?
| Tomography Scanners, X-Ray Computed | 1 | 2006 | 12 | 0.020 |
Why?
| Chromosomal Instability | 1 | 2006 | 16 | 0.020 |
Why?
| Neoplasm, Residual | 1 | 2007 | 165 | 0.020 |
Why?
| Cryopreservation | 1 | 2006 | 31 | 0.020 |
Why?
| Genome, Viral | 1 | 2006 | 79 | 0.020 |
Why?
| Analysis of Variance | 1 | 2007 | 562 | 0.020 |
Why?
| Nurse Practitioners | 1 | 2006 | 42 | 0.020 |
Why?
| Transfection | 1 | 2006 | 354 | 0.020 |
Why?
| Mutation, Missense | 1 | 2006 | 105 | 0.020 |
Why?
| Gynecology | 1 | 2006 | 49 | 0.020 |
Why?
| Gene Expression | 1 | 2008 | 609 | 0.020 |
Why?
| Ovarian Cysts | 1 | 2005 | 4 | 0.020 |
Why?
| Sarcoma, Endometrial Stromal | 1 | 2005 | 1 | 0.020 |
Why?
| Medical Futility | 1 | 2005 | 8 | 0.020 |
Why?
| Early Diagnosis | 1 | 2006 | 88 | 0.020 |
Why?
| Cyclophosphamide | 1 | 2006 | 165 | 0.020 |
Why?
| Triage | 1 | 2006 | 62 | 0.020 |
Why?
| Leiomyosarcoma | 1 | 2005 | 23 | 0.020 |
Why?
| Hospice Care | 1 | 2005 | 26 | 0.020 |
Why?
| Cytodiagnosis | 1 | 2005 | 42 | 0.020 |
Why?
| Health Services | 1 | 2005 | 67 | 0.020 |
Why?
| Phosphorylation | 1 | 2006 | 535 | 0.020 |
Why?
| Obstetrics | 1 | 2006 | 88 | 0.020 |
Why?
| Lymphatic System | 1 | 2004 | 14 | 0.020 |
Why?
| Penetrance | 1 | 2004 | 6 | 0.010 |
Why?
| Microscopy, Electron, Transmission | 1 | 2004 | 75 | 0.010 |
Why?
| Area Under Curve | 1 | 2004 | 182 | 0.010 |
Why?
| Calcification, Physiologic | 1 | 2004 | 41 | 0.010 |
Why?
| Laparotomy | 1 | 2004 | 34 | 0.010 |
Why?
| Bryostatins | 1 | 2003 | 1 | 0.010 |
Why?
| Macrolides | 1 | 2003 | 16 | 0.010 |
Why?
| Ethanol | 1 | 2006 | 340 | 0.010 |
Why?
| Genomic Instability | 1 | 2004 | 92 | 0.010 |
Why?
| Thrombospondin 1 | 1 | 2003 | 7 | 0.010 |
Why?
| Tamoxifen | 1 | 2004 | 60 | 0.010 |
Why?
| Genes, p16 | 1 | 2003 | 9 | 0.010 |
Why?
| Codon, Terminator | 1 | 2003 | 8 | 0.010 |
Why?
| Confidence Intervals | 1 | 2003 | 156 | 0.010 |
Why?
| Administration, Oral | 1 | 2004 | 426 | 0.010 |
Why?
| Frameshift Mutation | 1 | 2003 | 17 | 0.010 |
Why?
| Liposomes | 1 | 2003 | 48 | 0.010 |
Why?
| Mutagenesis, Insertional | 1 | 2003 | 24 | 0.010 |
Why?
| Palliative Care | 1 | 2005 | 187 | 0.010 |
Why?
| Body Weight | 1 | 2005 | 513 | 0.010 |
Why?
| Cytoskeletal Proteins | 1 | 2003 | 49 | 0.010 |
Why?
| DNA Transposable Elements | 1 | 2003 | 107 | 0.010 |
Why?
| Physicians | 1 | 2006 | 233 | 0.010 |
Why?
| Prevalence | 1 | 2006 | 944 | 0.010 |
Why?
| Reference Values | 1 | 2003 | 310 | 0.010 |
Why?
| Retinoblastoma-Like Protein p130 | 1 | 2002 | 8 | 0.010 |
Why?
| beta Catenin | 1 | 2003 | 102 | 0.010 |
Why?
| Retinoblastoma Protein | 1 | 2002 | 19 | 0.010 |
Why?
| Ifosfamide | 1 | 2002 | 9 | 0.010 |
Why?
| Documentation | 1 | 2002 | 34 | 0.010 |
Why?
| Trans-Activators | 1 | 2003 | 134 | 0.010 |
Why?
| Bleomycin | 1 | 2002 | 35 | 0.010 |
Why?
| Hospitals, University | 1 | 2002 | 77 | 0.010 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2002 | 74 | 0.010 |
Why?
| Age Distribution | 1 | 2002 | 168 | 0.010 |
Why?
| Equipment Failure | 1 | 2001 | 62 | 0.010 |
Why?
| Statistics, Nonparametric | 1 | 2002 | 194 | 0.010 |
Why?
| Nucleic Acid Hybridization | 2 | 1991 | 54 | 0.010 |
Why?
| Antibiotics, Antineoplastic | 1 | 2002 | 78 | 0.010 |
Why?
| Carcinoma, Small Cell | 1 | 2001 | 25 | 0.010 |
Why?
| Genes, erbB-1 | 1 | 2001 | 8 | 0.010 |
Why?
| Outpatients | 1 | 2002 | 113 | 0.010 |
Why?
| Radiography | 1 | 2002 | 489 | 0.010 |
Why?
| Hospitalization | 1 | 2005 | 652 | 0.010 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 2000 | 96 | 0.010 |
Why?
| DNA | 1 | 2004 | 541 | 0.010 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2001 | 155 | 0.010 |
Why?
| Genetic Linkage | 1 | 2000 | 26 | 0.010 |
Why?
| Chromosomes, Human, Pair 2 | 1 | 2000 | 25 | 0.010 |
Why?
| Morbidity | 1 | 2000 | 133 | 0.010 |
Why?
| Blotting, Western | 1 | 2001 | 601 | 0.010 |
Why?
| Gene Deletion | 1 | 2000 | 266 | 0.010 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2001 | 154 | 0.010 |
Why?
| Chromosomes, Bacterial | 1 | 1998 | 14 | 0.010 |
Why?
| Cloning, Molecular | 1 | 1998 | 185 | 0.010 |
Why?
| Infant | 1 | 2006 | 3567 | 0.010 |
Why?
| Child, Preschool | 1 | 2006 | 3871 | 0.010 |
Why?
| Drug Resistance, Multiple | 1 | 1997 | 23 | 0.010 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 1997 | 69 | 0.010 |
Why?
| Gene Frequency | 1 | 1997 | 94 | 0.010 |
Why?
| United States | 1 | 2007 | 4860 | 0.010 |
Why?
| Dimethyl Sulfoxide | 1 | 1994 | 12 | 0.010 |
Why?
| Ambulatory Surgical Procedures | 1 | 1995 | 46 | 0.010 |
Why?
| Glycerol | 1 | 1994 | 15 | 0.010 |
Why?
| Drug Carriers | 1 | 1994 | 67 | 0.010 |
Why?
| Drug Screening Assays, Antitumor | 1 | 1994 | 136 | 0.010 |
Why?
| Cell Cycle | 1 | 1994 | 231 | 0.010 |
Why?
| Retroperitoneal Space | 1 | 1991 | 30 | 0.010 |
Why?
|
|
Rader's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|